



Publikationsliste 2015

Originalarbeiten

1. Abdelhady W, Chen L, Bayer AS, Seidl K, Yeaman MR, Kreiswirth BN, Xiong YQ. Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections. *Journal of Antimicrobial Chemotherapy* 2015; 70(5): 1443-52.
2. Achermann Y, Seidl K, Kuster SP, Leimer N, Durisch N, Ajdler-Schäffler E, Karrer S, Senn G, Holzmann-Bürgel A, Wolfensberger A, Leone A, Arlettaz R, Zinkernagel AS, Sax H. Epidemiology of Methicillin-Susceptible *Staphylococcus aureus* in a Neonatology Ward. *Infection Control and Hospital Epidemiology* 2015; 1-8.
3. Achermann Y, Tran B, Kang M, Harro JM, Shirliff ME. Immunoproteomic identification of in vivo-produced propionibacterium acnes proteins in a rabbit biofilm infection model. *Clinical and Vaccine Immunology* 2015; 22(5): 467-76.
4. Anagnostopoulos A, Ledergerber B, Jaccard R, Shaw SA, Stoeckle M, Bernasconi E, Barth J, Calmy A, Berney A, Jenewein J, Weber R. Frequency of and risk factors for depression among participants in the Swiss HIV Cohort Study (SHCS). *PLoS ONE* 2015; 10(10): e0140943.
5. Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard P-M, Hill AM, Moecklinghoff C. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. *AIDS* 2015; 29(14): 1811-20.
6. Beeler PE, Kuster SP, Eschmann E, Weber R, Blaser J. Earlier switching from intravenous to oral antibiotics owing to electronic reminders. *International Journal of Antimicrobial Agents* 2015; 46(4): 428-33.
7. Berger C, Bochud P-Y, Boggian K, Cusini A, Egli A, Garzoni C, Hirsch HH, Hoffmann M, Khanna N, Manuel O, Meylan P, Nadal D, van Delden C, Weisser M, Mueller NJ. The swiss transplant cohort study: lessons from the first 6 years. *Current Infectious Disease Reports* 2015; 17(6): 17:29.
8. Bihl F, Martinetti G, Wandeler G, Weber R, Ledergerber B, Calmy A, Battegay M, Cavassini M, Vernazza P, Caminada A-P, Rickenbach M, Bernasconi E. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. *BMC Gastroenterology* 2015; 15: 79.
9. Birger R, Kouyos R, Dushoff J, Grenfell B. Modeling the effect of HIV coinfection on clearance and sustained virologic response during treatment for hepatitis C virus. *Epidemics* 2015; 12: 1-10.



10. Boillat-Blanco N, Darling KE, Schoni-Affolter F, Vuichard D, Rougemont M, Fulchini R, Bernasconi E, Aouri M, Clerc O, Furrer H, Günthard HF, Cavassini M. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. *Antiviral Therapy* 2015; 20(2): 165-75.
11. Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Günthard HF. Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. *Clinical Infectious Diseases* 2015; 61(6): 1013-21.
12. Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J. A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV/Hepatitis C coinfecting patients. *PLoS ONE* 2015; 10(7): e0133028.
13. Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, Wainberg MA, Speck RF, Scherrer D, Tazi J. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. *Retrovirology* 2015; 12(30): online.
14. Carballo D, Delhumeau C, Carballo S, Bähler C, Radovanovic D, Hirschel B, Clerc O, Bernasconi E, Fasel D, Schmid P, Cusini A, Fehr J, Erne P, Keller P-F, Ledergerber B, Calmy A. Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. *AIDS Research and Therapy* 2015; 12(4): online.
15. Ciaffi L, Cavassini M, Genne D, Delhumeau C, Spycher Elbes R, Hill A, Wandeler G, Fehr J, Stoeckle M, Schmid P, Hirschel B, Montecucco F, Calmy A. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. *European Journal of Clinical Investigation* 2015; 45(7): 720-30.
16. Cippa PE, Schiesser M, Ekberg H, van Gelder T, Mueller NJ, Cao CA, Fehr T, Bernasconi C. Risk Stratification for Rejection and Infection after Kidney Transplantation. *Clin J Am Soc Nephrol* 2015; 10(12): 2213-20.
17. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *Journal of Antimicrobial Chemotherapy* 2015; 70(3): 930-40.
18. Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, Günthard HF, Gardiner C, Klenerman P. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut* 2015; 64(5): 813-9.



19. Gallant JE, Koenig E, Andrade-Villanueva JF, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Rizzardini G, Fehr J, Liu HC, Abram ME, Cao H, Swarcberg J. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. *Journal of Acquired Immune Deficiency Syndromes* 2015; 69(3): 338-40.
20. Glass TR, Sterne JAC, Schneider M-P, De Geest S, Nicca D, Furrer H, Günthard HF, Bernasconi E, Calmy A, Rickenbach M, Battegay M, Bucher HC. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. *AIDS* 2015; 29(16): 2195-200.
21. Gueler A, Schoeni-Affolter F, Moser A, Bertisch B, Bucher HC, Calmy A, Cavassini M, Ledergerber B, Wandeler G, Egger M. Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. *AIDS* 2015; 29(2): 231-8.
22. Hachfeld A, Ledergerber B, Darling K, Weber R, Calmy A, Battegay M, Sugimoto K, Di Benedetto C, Fux CA, Tarr PE, Kouyos R, Furrer H, Wandeler G. Reasons for late presentation to HIV care in Switzerland. *Journal of the International Aids Society* 2015; 18(1): 20317.
23. Hasse B, Tarr PE, Marques-Vidal P, Waeber G, Preisig M, Mooser V, Valeri F, Djalali S, Andri R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Battegay M, Weber R, Senn O, Vollenweider P, Ledergerber B, CoLaus Cohort F, the Swiss HIVCS. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. *Open Forum Infect Dis* 2015; 2(3): ofv108.
24. Husmann L, Sah B-R, Scherrer A, Burger IA, Stolzmann P, Weber R, Rancic Z, Mayer D, Hasse B. 18F-FDG PET/CT for therapy control in vascular graft infections: a first feasibility study. *Journal of Nuclear Medicine* 2015; 56(7): 1024-9.
25. Kohler I, Kouyos R, Bianchi M, Grube C, Wyrzucki A, Günthard HF, Hangartner L. The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. *AIDS* 2015; 29(14): 1803-10.
26. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, Rössle M, Böni C, Falk V, Wilhelm MJ, Sommerstein R, Achermann Y, Ten Oever J, Debast SB, Wolfhagen MJHM, Brandon Bravo Bruinsma GJ, Vos MC, Bogers A, Serr A, Beyersdorf F, Sax H, Böttger EC, Weber R, van Ingen J, Wagner D, Hasse B. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery. *European Heart Journal* 2015; 36(40): 2745-53.
27. Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, Battegay M, Bernasconi E, Ledergerber B, Vernazza P. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. *AIDS* 2015; 29(18): 2509-15.



28. Kohler P, Sommerstein R, Schönrrath F, Ajdler-Schäffler E, Anagnostopoulos A, Tschirky S, Falk V, Kuster SP, Sax H. Effect of perioperative mupirocin and antiseptic body wash on infection rate and causative pathogens in patients undergoing cardiac surgery. *American Journal of Infection Control* 2015; 43(7): e33-e8.
29. Kouyos RD, Hasse B, Calmy A, Cavassini M, Furrer H, Stockle M, Vernazza PL, Bernasconi E, Weber R, Gunthard HF, Swiss HIVCS. Increases in Condomless Sex in the Swiss HIV Cohort Study. *Open Forum Infect Dis* 2015; 2(2): ofv077.
30. Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stockle M, Bernasconi E, Kouyos R, Weber R, Rauch A, Swiss HIVCS. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. *J Hepatol* 2015; 63(3): 573-80.
31. Kovari H, Russmann S, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF, Study SHC. Ribavirin concentrations do not predict sustained virological response in HIV/HCV-coinfected patients treated with ribavirin and pegylated interferon in the Swiss HIV Cohort Study. *PLoS ONE* 2015; 10(7): e0133879.
32. Leierer G, Grabmeier-Pfistershammer K, Steuer A, Geit M, Sarcletti M, Haas B, Kanatschnig M, Rappold M, Zangerle R, Ledergerber B, Taylor N, Group AHCS. Factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study. *PLoS ONE* 2015; 10(11): e0142923.
33. Leuthard D, Berger C, Staubli G, Nadal D, Schmid S, Hamer D, Weber R, Schlägenhauf P. Management of children with travel-related illness evaluated in a pediatric emergency room. *The Pediatric Infectious Disease Journal* 2015; 34(12): 1279-82.
34. Lewandowska DW, Zagordi O, Zbinden A, Schuurmans MM, Schreiber P, Geissberger F-D, Huder JB, Böni J, Benden C, Mueller NJ, Trkola A, Huber M. Unbiased metagenomic sequencing complements specific routine diagnostic methods and increases chances to detect rare viral strains. *Diagnostic Microbiology and Infectious Disease* 2015; 83(2): 133-8.
35. Li D, Schlaepfer E, Audigé A, Rochat M-A, Ivic S, Knowlton CN, Kim B, Keppler OT, Speck RF. Vpx mediated degradation of SAMHD1 has only a very limited effect on lentiviral transduction rate in ex vivo cultured HSPCs. *Stem Cell Research* 2015; 15(2): 271-80.
36. Manuel O, Wójtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, Steiger J, Stern M, Egli A, Garzoni C, Binet I, Weisser M, Berger C, Cusini A, Meylan P, Pascual M, Bochud P-Y. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. *Journal of Infectious Diseases* 2015; 211(6): 906-14.



37. Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy F-A, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. *AIDS* 2015; 29(2): 193-200.
38. Matt U, Sharif O, Martins R, Knapp S. Accumulating evidence for a role of oxidized phospholipids in infectious diseases. *Cellular and Molecular Life Sciences* 2015; 72(6): 1059-71.
39. Matter-Walstra KW, Greiner M, Cusini A, Schiesser M, Ledergerber B, Fehr T, Mueller NJ. Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. *Transplant Infectious Disease* 2015; 17(3): 342-9.
40. Meloni M, Corti N, Müller D, Henning L, Gutteck U, von Braun A, Weber R, Fehr JS. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges. *Swiss Medical Weekly* 2015; 145: w14223.
41. Meyer Sauter PM, Leimer N, Chan PK, Rely C, Seidl K, Zinkernagel AS, Berger C. Methicillin-resistant *Staphylococcus aureus* eradication in young infants should include the diaper area and treat housing contacts. *Acta Paediatrica* 2015: e581-e4.
42. Milleret V, Buzzi S, Gehrig P, Ziogas A, Grossmann J, Schilcher K, Zinkernagel AS, Zucker A, Ehrbar M. Protein adsorption steers blood contact activation on engineered cobalt chromium alloy oxide layers. *Acta Biomaterialia* 2015; 24: 343-51.
43. Möllerherm H, Neumann A, Schilcher K, Blodkamp S, Zeitouni NE, Dersch P, Lüthje P, Naim HY, Zinkernagel AS, von Köckritz-Blickwede M. *Yersinia enterocolitica*-mediated degradation of neutrophil extracellular traps (NETs). *FEMS Microbiology Letters* 2015; 362(23): fnv192.
44. Montazeri H, Günthard HF, Yang W-L, Kouyos R, Beerwinkler N. Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance. *Biostatistics* 2015; 16(4): 713-26.
45. Mueller NJ, Tini GM, Weber A, Gaspert A, Husmann L, Bloemberg G, Boehler A, Benden C. Hepatitis From *Spiroplasma* sp. in an Immunocompromised Patient. *American Journal of Transplantation* 2015; 15(9): 2511-6.
46. Myburgh R, Ivic S, Pepper MS, Gers-Huber G, Li D, Audigé A, Rochat M-A, Jaquet V, Regenass S, Manz MG, Salmon P, Krause K-H, Speck RF. Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice. *Journal of Virology* 2015; 89(13): 6761-72.



47. Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy* 2015; 70(2): 382-95.
48. Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, Bhagani S, López-Cortés LF, Haberl A, Stoeckle M, Márquez M, Scholten S, de Los Santos-Gil I, Mauss S, Rivero A, Collado A, Delgado M, Rockstroh JK, Pineda JA. Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection: real-life safety and efficacy. *PLoS ONE* 2015; 10(4): e0125080.
49. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, King CH, Knopp S, Landouré A, N'Goran EK, Raso G, Scherrer AU, Sousa-Figueiredo JC, Stete K, Zhou X-N, Utzinger J. Toward measuring schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. *PLoS Neglected Tropical Diseases* 2015; 9(6): e0003821.
50. Perkins MR, Bartha I, Timmer JK, Liebner JC, Wolinsky D, Gunthard HF, Hauser C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Telenti A, Douek DC, Fellay J, Swiss HIVCS. The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. *J Infect Dis* 2015; 212(4): 578-84.
51. Ponroy N, Taveira A, Mueller NJ, Millard A-L. Statins demonstrate a broad anti-cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains. *Journal of Medical Virology* 2015; 87(1): 141-53.
52. Rac J, Haas F, Schumacher A, Middeldorp JM, Delecluse H-J, Speck RF, Bernasconi M, Nadal D. Telomerase activity impacts on epstein-barr virus infection of AGS cells. *PLoS ONE* 2015; 10(4): e0123645.
53. Sah B-R, Husmann L, Mayer D, Scherrer AU, Rancic Z, Puipe G, Weber R, Hasse B. Diagnostic performance of (18)F-FDG-PET/CT in vascular graft infections. *European Journal of Vascular and Endovascular Surgery* 2015; 49(4): 455-64.
54. Salmon S, Pittet D, Sax H, McLaws ML. The 'My five moments for hand hygiene' concept for the overcrowded setting in resource-limited healthcare systems. *Journal of Hospital Infection* 2015; 91(2): 95-9.
55. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rössle M, Falk V, Kuster SP, Böttger EC, Weber R. Prolonged Outbreak of *Mycobacterium chimaera* Infection After Open-Chest Heart Surgery. *Clinical Infectious Diseases* 2015; 61(1): 67-75.
56. Sax H, Clack L. Mental models: a basic concept for human factors design in infection prevention. *Journal of Hospital Infection* 2015; 89(4): 335-9.



57. Schaerer V, Haubitz S, Kovari H, Ledergerber B, Ambrosioni J, Cavassini M, Stoeckle M, Schmid P, Decosterd L, Aouri M, Böni J, Günthard HF, Furrer H, Metzner KJ, Fehr J, Rauch A. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. *HIV Medicine* 2015; 16(10): 599-607.
58. Schäfer J, Young J, Bernasconi E, Ledergerber B, Nicca D, Calmy A, Cavassini M, Furrer H, Battegay M, Bucher HC, Study SHC. Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. *HIV Medicine* 2015; 16(1): 3-14.
59. Schlagenhaut P, Weld L, Goorhuis A, Gautret P, Weber R, von Sonnenburg F, Lopez-Vélez R, Jensenius M, Cramer JP, Field VK, Odolini S, Gkrania-Klotsas E, Chappuis F, Malvy D, van Genderen PJJ, Mockenhaupt F, Jauréguiberry S, Smith C, Beeching NJ, Ursing J, Parola P, Grobusch MP. Travel-associated infection presenting in Europe (2008-12): An analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. *Lancet Infectious Diseases* 2015; 15(1): 55-64.
60. Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R, Study SHC. Progression of liver fibrosis in HIV/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy. *PLoS ONE* 2015; 10(9): e0138838.
61. Schmied L, Terszowski G, Gonzalez A, Schmitter K, Hirsch HH, Garzoni C, van Delden C, Boggian K, Mueller NJ, Berger C, Villard J, Manuel O, Meylan P, Hess C, Stern M. Protection from varicella zoster in solid organ transplant recipients carrying killer cell immunoglobulin-like receptor B haplotypes. *Transplantation* 2015; 99(12): 2651-5.
62. Schreiber PW, Aceto L, Korach R, Marreros N, Ryser-Degiorgis M-P, Günthard HF. Cluster of leptospirosis acquired through river surfing in Switzerland. *Open Forum Infectious Diseases* 2015; 2(3): ofv102.
63. Seidl K, Leimer N, Palheiros Marques M, Furrer A, Holzmann-Bürgel A, Senn G, Zbinden R, Zinkernagel AS. Clonality and antimicrobial susceptibility of methicillin-resistant *Staphylococcus aureus* at the University Hospital Zurich, Switzerland between 2012 and 2014. *Annals of Clinical Microbiology and Antimicrobials* 2015; 14(14): online.
64. Seifert D, Di Giallonardo F, Metzner KJ, Günthard HF, Beerenwinkel N. A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory. *Genetics* 2015; 199(1): 191-203.
65. Shalova IN, Lim JY, Chittechath M, Zinkernagel AS, Beasley F, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, Poidinger M, Melillo G, Nizet V, Arnalich F, López-Collazo E, Biswas SK. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1a. *Immunity* 2015; 42(3): 484-98.



66. Sommerstein R, Kohler P, Wilhelm MJ, Kuster SP, Sax H. Factors associated with methicillin-resistant coagulase-negative staphylococci as causing organisms in deep sternal wound infections after cardiac surgery. *New Microbes and New Infections* 2015; 6: 15-21.
67. Ussher JE, Phalora P, Cosgrove C, Hannaway RF, Rauch A, Günthard HF, Goulder P, Phillips RE, Willberg CB, Klenerman P. Molecular analyses define Va7.2-Ja33+ MAIT cell depletion in HIV infection: a case-control study. *Medicine* 2015; 94(29): e1134.
68. Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard H, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M, Group ECS. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. *HIV Medicine* 2015; 16(5): 297-306.
69. von Braun A, Sekaggya C, Henning L, Nakijoba R, Kambugu A, Fehr J, Castelnovo B. 'If at first you don't succeed, try again'. Looking beyond the initial results of a failed tuberculosis diagnosis. *Public Health Action* 2015; 5(3): 170-2.
70. von Braun A, Thomas Y, Sax H. Do high-touch surfaces in public spaces pose a risk for influenza transmission? A virologic study during the peak of the 2009 influenza A(H1N1) pandemic in Geneva, Switzerland. *American Journal of Infection Control* 2015; 43(12): 1372-3.
71. Vongrad V, Imig J, Mohammadi P, Kishore S, Jaskiewicz L, Hall J, Günthard HF, Beerenwinkel N, Metzner KJ. HIV-1 RNAs are not part of the argonaute 2 associated RNA interference pathway in macrophages. *PLoS ONE* 2015; 10(7): e0132127.
72. Vrancken B, Lemey P, Rambaut A, Bedford T, Longdon B, Günthard HF, Suchard MA. Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution. *Methods Ecol Evol* 2015; 6(1): 67-82.
73. Wandeler G, Schlauri M, Jaquier ME, Rohrbach J, Metzner KJ, Fehr J, Ambrosioni J, Cavassini M, Stockle M, Schmid P, Bernasconi E, Keiser O, Salazar-Vizcaya L, Furrer H, Rauch A, Swiss HIVCS. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. *Open Forum Infect Dis* 2015; 2(1): ofv026.
74. Weber R, Huber M, Battegay M, Stähelin C, Castro Batanjer E, Calmy A, Bregenzer A, Bernasconi E, Schoeni-Affolter F, Ledergerber B. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. *HIV Medicine* 2015; 16(3): 137-51.



75. Wójtowicz A, Gresnigt MS, Lecompte T, Bibert S, Manuel O, Joosten LAB, Rüeger S, Berger C, Boggian K, Cusini A, Garzoni C, Hirsch HH, Weisser M, Mueller NJ, Meylan PR, Steiger J, Kutalik Z, Pascual M, van Delden C, van de Veerdonk FL, Bochud P-Y. IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. *Journal of Infectious Diseases* 2015; 211(10): 1646-57.
76. Wójtowicz A, Lecompte TD, Bibert S, Manuel O, Rüeger S, Berger C, Boggian K, Cusini A, Garzoni C, Hirsch H, Khanna N, Mueller NJ, Meylan PR, Pascual M, van Delden C, Bochud P-Y, Swiss Transplant Cohort Study. PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant. *Clinical Infectious Diseases* 2015; 61(4): 619-22.
77. Wolfensberger A, Durisch N, Mertin J, Ajdler-Schaeffler E, Sax H. Evaluating the tolerability and acceptability of an alcohol-based hand rub - real-life experience with the WHO protocol. *Antimicrobial Resistance and Infection Control* 2015; 4(18): online.
78. Yang W-L, Kouyos R, Scherrer AU, Böni J, Shah C, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Held L, Ledergerber B, Günthard HF, Study SHC. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV cohort study from 1998 to 2012. *Journal of Infectious Diseases* 2015; 212(1): 28-38.
79. Yang W-L, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, Scherrer AU, Shilaih M, Hinkley T, Petropoulos C, Bonhoeffer S, Günthard HF. Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. *PLoS Pathogens* 2015; 11(3): e1004722.
80. Yang W-L, Kouyos RD, Scherrer AU, Böni J, Shah C, Yerly S, Klimkait T, Aubert V, Hirzel C, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Held L, Ledergerber B, Günthard HF. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the swiss HIV cohort study. *Journal of Antimicrobial Chemotherapy* 2015: 3323-31.
81. Young J, Rickenbach M, Calmy A, Bernasconi E, Staehelin C, Schmid P, Cavassini M, Battegay M, Günthard HF, Bucher HC, Swiss HIVCS. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. *BMC Infect Dis* 2015; 15: 382.
82. Young J, Xiao Y, Moodie EEM, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. *Journal of Acquired Immune Deficiency Syndromes* 2015; 69(4): 413-21.



83. Zimmermann K, Bastidas S, Knecht L, Kuster H, Vavricka SR, Günthard HF, Oxenius A. Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+T-cell activation during HIV-1 infection. *European Journal of Immunology* 2015; 45(11): 3107-13.
84. Zimmermann K, Liechti T, Haas A, Rehr M, Trkola A, Günthard HF, Oxenius A. The orientation of HIV-1 gp120 binding to the CD4 receptor differentially modulates CD4+ T cell activation. *Journal of Immunology* 2015; 194(2): 637-49.
85. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, Allegranzi B, Magiorakos A-P, Pittet D. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. *Lancet Infectious Diseases* 2015; 15(2): 212-24.
86. Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Campbell NK, Taka N, Awasom C, Metzner KJ, van Lunzen J, Feldt T. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. *Journal of Antimicrobial Chemotherapy* 2015; 70(3): 922-5.

Case Reports

1. Kohler P, Clemens R, Weber R. Aufflammen des heiligen Feuers. *Swiss Medical Forum = Schweizerisches Medizin-Forum* 2015; 34: 758-9.
2. Nussbaumer-Ochsner Y, Hasse BK, Valmaggia C, Krause M. A pneumonia leading to blindness. *BMJ Case Reports* 2015; 2015: online.
3. Ruehe B, Capaul R, Müller N, Sax H, Hasse B. Wie lautet Ihre Diagnose? *Praxis* 2015; 104(17): 893-5.
4. Schuurmans MM, Palheiros Marques M, Freitag L, Zinkernagel AS, Achermann Y. Biofilm formation in a permanent tracheal stent implanted for twenty-five years. *Respiration* 2015; 90(4): 327-8.

Übersichtsartikel / Reviews

1. Abela I, Günthard HF. Infektiöse Endokarditis. *info@herz+gefäss* 2015, 06:16-23.
2. Birger RB, Kouyos RD, Cohen T, Griffiths EC, Huijben S, Mina M, Volkova V, Grenfell B, Metcalf CJ. The potential impact of coinfection on antimicrobial chemotherapy and drug resistance. *Trends Microbiol* 2015; 23(9): 537-44.
3. Denner J, Mueller NJ. Preventing transfer of infectious agents. *International Journal of Surgery* 2015; 23(Pt B): 306-11.
4. Fehr T, Cippa PE, Mueller NJ. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? *Transpl Int* 2015; 28(12): 1351-6.



5. Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. *American Journal of Transplantation* 2015; 15(12): 3024-40.
6. Metcalf CJ, Birger RB, Funk S, Kouyos RD, Lloyd-Smith JO, Jansen VA. Five challenges in evolution and infectious diseases. *Epidemics* 2015; 10: 40-4.
7. Mueller NJ. Cytomegalovirus: why viral dynamics matter. *EBioMedicine* 2015; 2(7): 631.
8. Tarr P, Schmid P, Bernasconi E, Stoeckle M, Kovari H. HIV-Infektion. *Swiss Medical Forum = Schweizerisches Medizin-Forum* 2015; 15(2021): 479-85.
9. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2015 Update of the Drug Resistance Mutations in HIV-1. *Top Antivir Med* 2015; 23(4): 132-41.

Buchkapitel

1. Achermann Y, Glanzmann MC. PJI after elbow prosthesis. In: Zimmerli W. *Bone and Joint Infections From Microbiology to Diagnostics and Treatment*. New Jersey: Wiley Blackwell, 2015.
2. Weber R, Deplazes P, Mathis A. Microsporidia. In: Jorgensen JH, Pfaller MA, Carroll KC, et al. *Manual of Clinical Microbiology*. Washington DC: ASM Press, 2015:2209-19.

Andere Arbeiten

1. Kouyos RD, Günthard HF. Editorial commentary: the irreversibility of HIV drug resistance. *Clinical Infectious Diseases* 2015; 61(5): 837-9.
2. Pollock E, Hasse B. [CME. Pertussis]]. *Praxis (Bern 1994)* 2015; 104(18): 941-7; quiz 8-9.
3. Wójtowicz A, Lecompte TD, Bibert S, Manuel O, Rüeger S, Berger C, Boggian K, Cusini A, Garzoni C, Khanna N, Mueller NJ, Meylan PR, Pascual M, van Delden C, Bochud P-Y, Study STC. Reply to Cunha et al. *Clinical Infectious Diseases* 2015; 61(12): 1894-5.
4. Young J, Moodie EEM, Abrahamowicz M, Klein MB, Weber R, Bucher HC. Incomplete modeling of the effect of antiretroviral therapy on the risk of cardiovascular events. *Clinical Infectious Diseases* 2015; 61(7): 1206-7.



Habilitationen

1. Fehr J. Cofactors influencing morbidity and mortality of human immunodeficiency virus infected individuals in the era of highly active antiretroviral therapy.
Erteilung der Venia Legendi für das Gebiet Infektiologie.
Habilitation an der Medizinischen Fakultät der Universität Zürich, 2015.
2. Kouyos R. The molecular epidemiology and evolution of HIV-1 in the Swiss HIV Cohort Study.
Erteilung der Venia Legendi für das Gebiet Infektiologie, speziell molekulare Epidemiologie und mathematische Modellierung von Infektionskrankheiten.
Habilitation an der Medizinischen Fakultät der Universität Zürich, 2015.

Dissertationen

- 1 Gers-Huber Gustavo, Identification of cellular HIV restriction factors and host-HIV interactions
Dissertation an der Mathematisch Naturwissenschaftlichen Fakultät (PhD), 2015.
Leitung: Prof. Dr. med. R. Speck
2. Li Duo, The role of SOCS in HIV-1 pathogenesis in vivo.
Dissertation an der Mathematisch Naturwissenschaftlichen Fakultät (PhD), 2015.
Leitung: Prof. Dr. med. R. Speck
3. Myburgh Renier, Engineering an HIV-1 resistant immune system.
Dissertation an der Mathematisch Naturwissenschaftlichen Fakultät (PhD), 2015.
Leitung: Prof. Dr. med. R. Speck
4. Nischang Mark, Towards an in vivo HIV latency model using humanized mice.
Dissertation an ETH Zürich (Dr. sc. ETH Zürich), 2015.
Leitung: Prof. Dr. med. R. Speck
5. Schaerer V. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Dissertation an der Universität Zürich (MeF), 2015.
Leitung: PD Dr. J. Fehr
6. Yang Wan-Lin, Transmission of HIV-1 drug resistance and efficacy of antiretroviral treatment in the Swiss HIV Cohort Study.
Dissertation an der Mathematisch Naturwissenschaftlichen Fakultät (PhD), 2015.
Leitung: Prof. Dr. med. H. Günthard



Masterarbeiten

1. Balmer B. Klinische Präsentation der HIV-Primoinfektion in 290 Patienten aus der Zurich Primary HIV-1 Infection Study.
Masterarbeit an der Universität Zürich (MeF), 2015.
Leitung: Prof. Dr. Huldrych Günthard
2. Frauenfelder S. Predictors of treatment response and outcome among patients with prosthetic vascular graft infections.
Masterarbeit an der Universität Zürich (MeF), 2015.
Leitung: PD Dr. Barbara Hasse
3. Friedrich B. Review-Arbeit zum Wechsel und Outcome der ersten antiretroviralen Therapie bei HIV Patienten.
Masterarbeit an der Universität Zürich (MeF), 2015.
Leitung: Prof. Dr. Bruno Ledergerber, Prof. Dr. Rainer Weber
4. Ghenzi R. Inzidenz-Raten sexuell übertragbarer Infektionskrankheiten bei Patienten mit einer akuten HIV-Infektion aus der Zurich Primary HIV-Infektion Study im Zeitraum 2002 bis 2013.
Masterarbeit an der Universität Zürich (MeF), 2015.
Leitung: Prof. Dr. Huldrych Günthard
5. Palheiros Marques M. Characterization of clinical Staphylococcus aureus isolates by genetic typing, induction of endothelial cell damage and intracellular localization.
Leitung: Prof. Dr. Annelies Zinkernagel
6. Rachmühl C. Induction and eradication of Staphylococcus aureus small colony variants.
Masterarbeit an der Universität Zürich (MNF), 2015.
Leitung: Prof. Dr. Annelies Zinkernagel